Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Der nächste Perpetua? Warum NevGolds neueste Bohrergebnisse den Vergleich mit dem Milliardenwert PPTA nähren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H48J | ISIN: SE0009973563 | Ticker-Symbol: 6XP
Frankfurt
06.06.25 | 15:29
2,710 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XSPRAY PHARMA AB Chart 1 Jahr
5-Tage-Chart
XSPRAY PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
2,7503,02012:37

Aktuelle News zur XSPRAY PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.XSpray Pharma AB: FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc133The U.S. Food and Drug Administration (FDA) has acknowledged receipt of Xspray Pharma's re-submitted NDA (New Drug Application) for Dasynoc®. The re-submission is based on a CRL (Complete Response Letter)...
► Artikel lesen
13.05.XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ)64The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 13 May 2025. Adoption of income statement and balance sheet for the financial...
► Artikel lesen
07.05.XSpray Pharma AB: Interim Report First Quarter 202563January - March 2025, Group• Net sales amounted to SEK 0 thousand (0)• Earnings before tax amounted to SEK -42,321 thousand (-67,781)• Earnings per share before dilution amounted to SEK -1.14 (-2.17)•...
► Artikel lesen
XSPRAY PHARMA Aktie jetzt für 0€ handeln
08.04.XSpray Pharma AB: Xspray Pharma re-submits its FDA application160Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc®, the company's lead product candidate, an amorphous dasatinib for the treatment of leukemia. The application...
► Artikel lesen
12.02.XSpray Pharma AB: Interim Report Fourth Quarter 202470October-December 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,002 thousand (-54,513)Earnings per share before dilution amounted to SEK -2.36 (-1.85)Cash flow...
► Artikel lesen
20.01.XSpray Pharma AB: Xspray Pharma reports strong interim data for product candidate XS003 - confirms plan to apply for market approval in H1 2025100Xspray Pharma AB (publ) today presents interim data from a food interaction study with the nilotinib product candidate (XS003). The results confirm the benefits of the company's patented HyNap technology...
► Artikel lesen
14.11.24Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Xspray Pharma AB337With effect from November 15, 2024, the subscription rights of Xspray Pharma AB will be traded on the list for Equity rights. Trading will continue up until and including November 26, 2024. Instrument:...
► Artikel lesen
12.11.24XFRA CAPITAL ADJUSTMENT INFORMATION - 12.11.20242.426Das Instrument 3O41 BMG611881019 LIBERTY GLOBAL LTD CL.A EQUITY wird cum Kapitalmassnahme gehandelt am 12.11.2024 und ex Kapitalmassnahme am 13.11.2024 The instrument 3O41 BMG611881019 LIBERTY GLOBAL...
► Artikel lesen
06.11.24XSpray Pharma AB: Interim Report Third Quarter 2024145July - September 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,272 thousand (-38,942)Earnings per share before dilution amounted to SEK -2.44 (-1.59)Cash flow...
► Artikel lesen
06.11.24XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 135 million and raises a loan of SEK 100 million191THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH...
► Artikel lesen
19.09.24Xspray Pharma AB: Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission326Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology to develop enhanced cancer therapies, today announced significant progress...
► Artikel lesen
06.09.24Scientific Article in Leading Journal Endorses Xspray Pharma's HyNap Technology446A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap technology improves the bioavailability and reduces variability of...
► Artikel lesen
07.08.24XSpray Pharma AB: Interim Report Second Quarter 2024163April-June 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -53,620 thousand (-51,402)Earnings per share before dilution amounted to SEK -1.64 (-2.27)Cash flow from...
► Artikel lesen
26.07.24XSpray Pharma AB: Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development484Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Dasynoc...
► Artikel lesen
09.07.24Xspray Pharma AB: Xspray Pharma's XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose395Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. Xspray Pharma AB (Stockholm/Nasdaq:...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1